iNtODEWORLD | Our research is committed to finding effective treatment for life-threatening infectious diseases.
15234
home,page,page-id-15234,page-template,page-template-full_width,page-template-full_width-php,qode-quick-links-1.0,ajax_fade,page_not_loaded,,qode-title-hidden,qode_grid_1300,qode-theme-ver-11.0,qode-theme-bridge,wpb-js-composer js-comp-ver-5.1.1,vc_responsive

iNtODEWORLD

A Game Changer in Antibacterial Drugs for Superbugs and Persister Cells

We are committed to finding effective treatment for life-threatening infectious diseases.

maintopban1

A Game Changer in Antibacterials Treatment for Gram-negative bacteria, Ultimate Target of N-Rephasin® Technology

maintopban2

Eco-friendly, no Side-effects, Unique mode of action. Bacteriophages and Antibiotic Resistance in Bacteria

maintopban3

Opening a New Era in Anti-Fugal Agents. A New Type of Antifungal Agent, iN-EYD34

maintopban4

New Generation of Heme-Iron (Porphyrin-Fe) Novel concept iron deficiency anemia therapeutic agent

iNtRON Biotechnology, Inc.

iNtRON Bio has been focusing on the R&D investment since its foundation and accelerates development speed after the IPO in KOSDAQ. We are aiming for the ‘global R&D company’ ; and promoting the value of the company focused on the BIO New Drug by developing various ‘First-in-Class’ bio-drugs and conducting clinical studies in phases.

INSIDE iNtRON

  • Arixa Pharmaceuticals™, Inc., a company dedicated to developing next-generation oral antibiotics for drug-resistant Gram-negative infections today announced that Pfizer’s Hospital Business has agreed to acquire Arixa. Arixa’s lead compound, ARX-1796, is an oral prodrug of avibactam, a beta lactamase inhibitor (BLI) that was FDA-approved in 2015 as part......

  • iNtRON Biotechnology has developed a LiliF™ GBN COVID-19 IgG Rapid Kit. LiliF™ GBN COVID-19 IgG Rapid Kit is a lateral flow chromatographic immunoassay for the detection of anti-SARS-CoV-2 IgG antibodies in human whole blood, serum or plasma. It is intended to be used by professionals......

  • In most recent news, Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company, announced that the Department of Defense (DoD) has awarded them $9.8 million for the research development of multiple Phase-1  high-priority, bacteriophage-based vaccine candidates against SARS-CoV-2. APT research contract with the DoD will only advance......

See All
seh

PIPELINES

iNtRON Bio has been focusing on the R&D investment since its foundation and accelerate development speed after the IPD in KOSDAQ. We are aiming for the ‘global R&D company’ ; and promoting the value of the company focused on the BIO New Drug by developing various ‘First-in-Class’ bio-drugs and conducting clinical studies in phases.

iNtODEWORLD, Inc is the US subsidiary of iNtRON Biotechnology, Inc.
PGlmcmFtZSB3aWR0aD0iNzAwIiBoZWlnaHQ9IjM5NCIgc3JjPSJodHRwczovL3d3dy55b3V0dWJlLmNvbS9lbWJlZC81UDMxdTh6emF6az9yZWw9MCIgZnJhbWVib3JkZXI9IjAiIGFsbG93PSJhdXRvcGxheTsgZW5jcnlwdGVkLW1lZGlhIiBhbGxvd2Z1bGxzY3JlZW4+PC9pZnJhbWU+